Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study

被引：7
作者：
Abe, Hiroko [1 ]
Mita, Tomoya [1 ,2 ]
Yamamoto, Risako [1 ]
Komiya, Koji [1 ]
Kawaguchi, Minako [1 ]
Sakurai, Yuko [1 ]
Shimizu, Tomoaki [1 ]
Ohmura, Chie [1 ]
Ikeda, Fuki [1 ]
Kawamori, Ryuzo [3 ]
Fujitani, Yoshio [1 ,4 ]
Watada, Hirotaka [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Dept Metab & Endocrinol, Tokyo, Japan
[2] Juntendo Univ, Grad Sch Med, Ctr Mol Diabetol, Tokyo, Japan
[3] Juntendo Univ, Grad Sch Med, Sportol Ctr, Tokyo, Japan
[4] Juntendo Univ, Grad Sch Med, Ctr Beta Cell Biol & Regenerat, Tokyo, Japan
[5] Juntendo Univ, Grad Sch Med, Ctr Therapeut Innovat Diabet, Tokyo, Japan
来源：
JOURNAL OF DIABETES INVESTIGATION | 2013年 / 4卷 / 02期
关键词：
Albuminuria; Calcium channel blocker; Diabetes; CALCIUM-CHANNEL BLOCKER; SERUM URIC-ACID; NEPHROPATHY; MECHANISMS; AMLODIPINE; OLMESARTAN; RELEASE; DISEASE;
D O I：
10.1111/jdi.12003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Previous studies reported that both cilnidipine and azelnidipine have a renoprotective effect compared with amlodipine. The aim of this study was to compare the effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria. An open-label prospective crossover trial was carried out. We recruited 19 type 2 diabetics treated with amlodipine (5mg/day) at least for 12weeks. At study entry, amlodipine was changed to cilnidipine (10mg/day) or azelnidipine (16mg/day) and each administered for 16weeks. Then, the drugs were switched and the treatment was continued for another 16weeks. Despite no differences in 24-h blood pressure and heart rate between cilnidipine and azelnidipine, treatment with cilnidipine resulted in a greater reduction in urinary albumin:creatinine ratio than azelnidipine. Our results suggested that cilnidipine is more efficient in reducing albuminuria than azelnidipine independent of its blood pressure lowering effect in type 2 diabetic patients with hypertension. This trial was registered with UMIN (no. 000007201).
引用
收藏
页码：202 / 205
页数：4
相关论文
共 23 条
[1]   Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria [J].
Abe, Masanori ;
Maruyama, Noriaki ;
Okada, Kazuyoshi ;
Matsumoto, Shiro ;
Matsumoto, Koichi ;
Soma, Masayoshi .
HYPERTENSION RESEARCH, 2011, 34 (08) :935-941
[2]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[3]   Disease-dependent mechanisms of albuminuria [J].
Comper, Wayne D. ;
Hilliard, Lucinda M. ;
Nikolic-Paterson, David J. ;
Russo, Leileata M. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2008, 295 (06) :F1589-F1600
[4]   Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte [J].
Fan, Yu-Yan ;
Kohno, Masakazu ;
Nakano, Daisuke ;
Ohsaki, Hiroyuki ;
Kobori, Hiroyuki ;
Diah, Suwarni ;
Ohashi, Naro ;
Hitomi, Hirofumi ;
Asanuma, Katsuhiko ;
Noma, Takahisa ;
Tomino, Yasuhiko ;
Fujita, Toshiro ;
Nishiyama, Akira .
JOURNAL OF HYPERTENSION, 2010, 28 (05) :1034-1043
[5]   Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease [J].
Fujita, T. ;
Ando, K. ;
Nishimura, H. ;
Ideura, T. ;
Yasuda, G. ;
Isshiki, M. ;
Takahashi, K. .
KIDNEY INTERNATIONAL, 2007, 72 (12) :1543-1549
[6]   Serum uric acid is associated with micro albuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus [J].
Fukui, Michiaki ;
Tanak, Muhei ;
Shiraishi, Emi ;
Harusato, Ichiko ;
Hosoda, Hiroko ;
Asano, Mai ;
Kadono, Mayuko ;
Hasegawa, Goji ;
Yoshikawa, Toshikazu ;
Nakamura, Naoto .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2008, 57 (05) :625-629
[7]   DOMINANT ROLE OF N-TYPE CA-2+ CHANNELS IN EVOKED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NEURONS [J].
HIRNING, LD ;
FOX, AP ;
MCCLESKEY, EW ;
OLIVERA, BM ;
THAYER, SA ;
MILLER, RJ ;
TSIEN, RW .
SCIENCE, 1988, 239 (4835) :57-61
[8]   Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure [J].
Hoshide, S ;
Kario, K ;
Ishikawa, J ;
Eguchi, K ;
Shimada, K .
HYPERTENSION RESEARCH, 2005, 28 (12) :1003-1008
[9]   Vasodilatory Effect of Cilnidipine, an L-type and N-type Calcium Channel Blocker, on Rat Kidney Glomerular Arterioles [J].
Konno, Yuusuke ;
Kimura, Kenjiro .
INTERNATIONAL HEART JOURNAL, 2008, 49 (06) :723-732
[10]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
123